Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
ABOS
Valuation N/A
Acumen Pharmaceuticals, Inc.
Price$2.10
Model IV—
P/IV—
Limited data — see page
ACOG
Valuation N/A
Alpha Cognition Inc.
Price$9.04
Model IV—
P/IV—
Market implies +25.9%/yr
ADMA
Deeply undervalued
ADMA BIOLOGICS, INC.
Price$10.33
Model IV$23.19
P/IV0.42
Discount 55%
Return to IV: +124.5%
Market implies -14.3%/yr
vs model +50.0% · below model
ADPT
Valuation N/A
Adaptive Biotechnologies Corp
Price$26.09
Model IV—
P/IV—
Market implies +33.9%/yr
AGEN
Valuation N/A
AGENUS INC
Price$7.54
Model IV—
P/IV—
Market implies +25.5%/yr
AGMB
Valuation N/A
AgomAb Therapeutics NV
Price$9.22
Model IV—
P/IV—
Limited data — see page
AIM
Valuation N/A
AIM ImmunoTech Inc.
Price$0.18
Model IV—
P/IV—
Market implies +15.6%/yr
ALEC
Valuation N/A
Alector, Inc.
Price$2.02
Model IV—
P/IV—
Market implies +54.4%/yr
ALGS
Valuation N/A
Aligos Therapeutics, Inc.
Price$5.31
Model IV—
P/IV—
Market implies +41.5%/yr
ALLO
Valuation N/A
Allogene Therapeutics, Inc.
Price$1.40
Model IV—
P/IV—
Market implies +150.0%/yr
ALVO
Deeply undervalued
Alvotech
Price$5.67
Model IV$13.26
P/IV0.46
Discount 57%
Return to IV: +133.9%
Market implies -14.4%/yr
vs model +50.0% · below model
ALVOW
Valuation N/A
Alvotech
Price$0.45
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +50.0% · below model
AMGN
Fairly valued
AMGEN INC
Price$407.44
Model IV$379.96
P/IV1.09
Premium +7%
Return to IV: -6.7%
Market implies +8.6%/yr
vs model +9.7% · in line
APGE
Valuation N/A
APGE
Price$135.07
Model IV—
P/IV—
Limited data — see page
ARGX
Deeply overvalued
ARGENX SE
Price$818.63
Model IV$213.97
P/IV4.48
Premium +283%
Return to IV: -73.9%
Market implies +14.5%/yr
vs model +15.0% · in line
ARMP
Valuation N/A
Armata Pharmaceuticals, Inc.
Price$3.86
Model IV—
P/IV—
Limited data — see page
ARTV
Valuation N/A
Artiva Biotherapeutics, Inc.
Price$6.80
Model IV—
P/IV—
Market implies +93.4%/yr
ATRA
Fairly valued
Atara Biotherapeutics, Inc.
Price$9.23
Model IV$9.49
P/IV0.89
Discount 3%
Return to IV: +2.9%
Market implies -2.9%/yr
vs model +15.0% · below model
ATYR
Valuation N/A
aTYR PHARMA INC
Price$0.26
Model IV—
P/IV—
Market implies +62.8%/yr
AURA
Valuation N/A
Aura Biosciences, Inc.
Price$6.51
Model IV—
P/IV—
Limited data — see page
AUTL
Valuation N/A
Autolus Therapeutics plc
Price$1.77
Model IV—
P/IV—
Market implies +24.0%/yr
AVXL
Valuation N/A
ANAVEX LIFE SCIENCES CORP.
Price$1.54
Model IV—
P/IV—
Limited data — see page
BCAB
Valuation N/A
BioAtla, Inc.
Price$1.55
Model IV—
P/IV—
Market implies +78.6%/yr
BCDA
Valuation N/A
BioCardia, Inc.
Price$1.06
Model IV—
P/IV—
Market implies +62.8%/yr
BCRX
Deeply undervalued
BIOCRYST PHARMACEUTICALS INC
Price$8.29
Model IV$41.86
P/IV0.20
Discount 80%
Return to IV: +404.9%
Market implies -8.3%/yr
vs model +17.8% · below model
BDTX
Deeply overvalued
Black Diamond Therapeutics, Inc.
Price$1.81
Model IV$0.77
P/IV2.44
Premium +134%
Return to IV: -57.3%
Market implies +13.0%/yr
vs model +15.0% · in line
BEAM
Valuation N/A
Beam Therapeutics Inc.
Price$24.60
Model IV—
P/IV—
Market implies +34.3%/yr
BIIB
Undervalued
BIOGEN INC.
Price$218.43
Model IV$265.46
P/IV0.83
Discount 18%
Return to IV: +21.5%
Market implies +2.7%/yr
vs model +6.2% · below model
BKHA
Valuation N/A
Black Hawk Acquisition Corp
Price$12.33
Model IV—
P/IV—
Limited data — see page
BKHAR
Valuation N/A
Black Hawk Acquisition Corp
Price$1.85
Model IV—
P/IV—
Limited data — see page
BKHAU
Valuation N/A
Black Hawk Acquisition Corp
Price$12.63
Model IV—
P/IV—
Limited data — see page
BNTX
Deeply overvalued
BioNTech SE
Price$92.06
Model IV$21.73
P/IV4.41
Premium +324%
Return to IV: -76.4%
Market implies +17.7%/yr
vs model +2.0% · above model
CABA
Valuation N/A
Cabaletta Bio, Inc.
Price$1.95
Model IV—
P/IV—
Limited data — see page
CADL
Valuation N/A
Candel Therapeutics, Inc.
Price$9.66
Model IV—
P/IV—
Market implies +132.4%/yr
CCCC
Valuation N/A
C4 Therapeutics, Inc.
Price$2.85
Model IV—
P/IV—
Market implies +41.4%/yr
CELZ
Valuation N/A
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Price$0.86
Model IV—
P/IV—
Market implies +80.7%/yr
CGEM
Valuation N/A
Cullinan Therapeutics, Inc.
Price$15.46
Model IV—
P/IV—
Market implies +53.4%/yr
vs model +15.0% · above model
CGEN
Deeply undervalued
COMPUGEN LTD
Price$2.12
Model IV$5.66
P/IV0.44
Discount 63%
Return to IV: +167.0%
Market implies -5.3%/yr
vs model +14.5% · below model
CGON
Valuation N/A
CG Oncology, Inc.
Price$63.26
Model IV—
P/IV—
Market implies +75.8%/yr
vs model +50.0% · above model
CGTX
Valuation N/A
COGNITION THERAPEUTICS INC
Price$0.90
Model IV—
P/IV—
Limited data — see page
CHRS
Valuation N/A
Coherus Oncology, Inc.
Price$1.07
Model IV—
P/IV—
Market implies +53.5%/yr
vs model +2.0% · above model
CLDI
Valuation N/A
Calidi Biotherapeutics, Inc.
Price$1.04
Model IV—
P/IV—
Market implies +150.0%/yr
CLLS
Deeply overvalued
Cellectis S.A.
Price$1.25
Model IV$0.95
P/IV1.64
Premium +31%
Return to IV: -23.8%
Market implies +3.3%/yr
vs model +24.5% · below model
CMPX
Valuation N/A
Compass Therapeutics, Inc.
Price$0.98
Model IV—
P/IV—
Market implies +70.2%/yr
vs model +15.0% · above model
COAG
Valuation N/A
Hemab Therapeutics Holdings, Inc.
Price$30.89
Model IV—
P/IV—
Limited data — see page
CRBU
Valuation N/A
Caribou Biosciences, Inc.
Price$0.48
Model IV—
P/IV—
Market implies +48.4%/yr
vs model +3.8% · above model
CRDF
Valuation N/A
Cardiff Oncology, Inc.
Price$1.06
Model IV—
P/IV—
Market implies +75.1%/yr
vs model +13.4% · above model
CRDL
Valuation N/A
Cardiol Therapeutics Inc.
Price$1.30
Model IV—
P/IV—
Limited data — see page
CRIS
Valuation N/A
CURIS INC
Price$0.71
Model IV—
P/IV—
Market implies +20.7%/yr
vs model +2.0% · above model
CRSP
Valuation N/A
CRISPR Therapeutics AG
Price$50.44
Model IV—
P/IV—
Market implies +147.0%/yr
CSBR
Deeply undervalued
CHAMPIONS ONCOLOGY, INC.
Price$4.98
Model IV$11.38
P/IV0.51
Discount 56%
Return to IV: +128.5%
Market implies -5.0%/yr
vs model +9.5% · below model
CVM
Valuation N/A
CEL SCI CORP
Price$1.95
Model IV—
P/IV—
Limited data — see page
DBVT
Valuation N/A
DBV Technologies S.A.
Price$9.55
Model IV—
P/IV—
Market implies +86.6%/yr
DNA
Valuation N/A
Ginkgo Bioworks Holdings, Inc.
Price$11.34
Model IV—
P/IV—
Market implies +63.1%/yr
vs model +2.0% · above model
DNLI
Valuation N/A
Denali Therapeutics Inc.
Price$18.67
Model IV—
P/IV—
Market implies +31.9%/yr
vs model +15.0% · above model
DTIL
Valuation N/A
PRECISION BIOSCIENCES INC
Price$6.43
Model IV—
P/IV—
Market implies +22.6%/yr
vs model +2.0% · above model
DYAI
Valuation N/A
DYADIC INTERNATIONAL INC
Price$0.44
Model IV—
P/IV—
Market implies +19.1%/yr
vs model +6.5% · above model
EDIT
Valuation N/A
Editas Medicine, Inc.
Price$2.84
Model IV—
P/IV—
Market implies +47.2%/yr
vs model +12.2% · above model
EIKN
Valuation N/A
Eikon Therapeutics, Inc.
Price$7.50
Model IV—
P/IV—
Limited data — see page
ELUT
Deeply overvalued
ELUTIA INC.
Price$0.83
Model IV$0.35
P/IV3.33
Premium +137%
Return to IV: -57.9%
Market implies +2.1%/yr
vs model +2.0% · in line